{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:36:35Z","timestamp":1790670995490,"version":"4.1.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,5,15]]},"abstract":"<jats:p>Dysregulated tyrosine kinase activity by the Fip1-like1 (FIP1L1)\u2013platelet-derived growth factor receptor alpha (PDGFRA) (F\/P) fusion gene has been identified as a cause of clonal hypereosinophilic syndrome (HES), called F\/P-positive chronic eosinophilic leukemia (CEL) in humans. However, transplantation of F\/P-transduced hematopoietic stem cells\/progenitors (F\/P+ HSCs\/Ps) into mice results in a chronic myelogenous leukemia\u2013like disease, which does not resemble HES. Because a subgroup of patients with HES show T-cell\u2013dependent interleukin-5 (IL-5) overexpression, we determined if expression of the F\/P fusion gene in the presence of transgenic T-cell IL-5 overexpression in mice induces HES-like disease. Mice that received a transplant of CD2-IL-5\u2013transgenic F\/P+ HSC\/Ps (IL-5Tg-F\/P) developed intense leukocytosis, strikingly high eosinophilia, and eosinophilic infiltration of nonhematopoietic as well as hematopoietic tissues, a phenotype resembling human HES. The disease phenotype was transferable to secondary transplant recipients of a high cell dose, suggesting involvement of a short-term repopulating stem cell or an early myeloid progenitor. Induction of significant eosinophilia was specific for F\/P since expression of another fusion oncogene, p210-BCR\/ABL, in the presence of IL-5 overexpression was characterized by a significantly lower eosinophilia than IL-5Tg-F\/P recipients. These results suggest that F\/P is not sufficient to induce a HES\/CEL-like disease but requires a second event associated with IL-5 overexpression.<\/jats:p>","DOI":"10.1182\/blood-2005-08-3153","type":"journal-article","created":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T03:28:20Z","timestamp":1137554900000},"page":"4071-4079","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)\/chronic eosinophilic leukemia (CEL)\u2013like disease"],"prefix":"10.1182","volume":"107","author":[{"given":"Yoshiyuki","family":"Yamada","sequence":"first","affiliation":[{"name":"From the Division of Allergy and Immunology and the Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH; and Hoxworth Blood Center, University of Cincinnati College of Medicine, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Rothenberg","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology and the Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH; and Hoxworth Blood Center, University of Cincinnati College of Medicine, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology and the Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH; and Hoxworth Blood Center, University of Cincinnati College of Medicine, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko Saito","family":"Akei","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology and the Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH; and Hoxworth Blood Center, University of Cincinnati College of Medicine, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Brandt","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology and the Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH; and Hoxworth Blood Center, University of Cincinnati College of Medicine, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Williams","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology and the Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH; and Hoxworth Blood Center, University of Cincinnati College of Medicine, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Cancelas","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Immunology and the Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH; and Hoxworth Blood Center, University of Cincinnati College of Medicine, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111906433378100_REF1","doi-asserted-by":"crossref","unstructured":"Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med. 1968;68: 1220-1229.","DOI":"10.7326\/0003-4819-68-6-1220"},{"key":"2019111906433378100_REF2","doi-asserted-by":"crossref","unstructured":"Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54: 1-27.","DOI":"10.1097\/00005792-197501000-00001"},{"key":"2019111906433378100_REF3","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348: 1201-1214.","DOI":"10.1056\/NEJMoa025217"},{"key":"2019111906433378100_REF4","doi-asserted-by":"crossref","unstructured":"Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 2003;100: 7830-7835.","DOI":"10.1073\/pnas.0932698100"},{"key":"2019111906433378100_REF5","unstructured":"La Starza R, Specchia G, Cuneo A, et al. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1\/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica. 2005;90: 596-601."},{"key":"2019111906433378100_REF6","doi-asserted-by":"crossref","unstructured":"Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104: 3038-3045.","DOI":"10.1182\/blood-2004-03-0787"},{"key":"2019111906433378100_REF7","doi-asserted-by":"crossref","unstructured":"Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PD-FGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18: 734-742.","DOI":"10.1038\/sj.leu.2403313"},{"key":"2019111906433378100_REF8","doi-asserted-by":"crossref","unstructured":"Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia. 2005;19: 792-798.","DOI":"10.1038\/sj.leu.2403722"},{"key":"2019111906433378100_REF9","doi-asserted-by":"crossref","unstructured":"Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101: 4660-4666.","DOI":"10.1182\/blood-2003-01-0006"},{"key":"2019111906433378100_REF10","doi-asserted-by":"crossref","unstructured":"Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103: 473-478.","DOI":"10.1182\/blood-2003-08-2798"},{"key":"2019111906433378100_REF11","doi-asserted-by":"crossref","unstructured":"Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101: 4714-4716.","DOI":"10.1182\/blood-2003-01-0081"},{"key":"2019111906433378100_","doi-asserted-by":"crossref","unstructured":"Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26: 881-884.","DOI":"10.1016\/S0145-2126(02)00046-2"},{"key":"2019111906433378100_REF13","doi-asserted-by":"crossref","unstructured":"Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002; 359: 1577-1578.","DOI":"10.1016\/S0140-6736(02)08505-7"},{"key":"2019111906433378100_REF14","doi-asserted-by":"crossref","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990;247: 824-830.","DOI":"10.1126\/science.2406902"},{"key":"2019111906433378100_REF15","doi-asserted-by":"crossref","unstructured":"Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3: 459-469.","DOI":"10.1016\/S1535-6108(03)00108-9"},{"key":"2019111906433378100_REF16","doi-asserted-by":"crossref","unstructured":"Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR{beta} and FIP1L1-PDGFR{alpha} in vitro and in vivo. Blood. Prepublished on July 19, 2005, as DOI 10.1182\/blood-2005-05-1932. (Now available as Blood. 2005;106:3206-3213.)","DOI":"10.1182\/blood-2005-05-1932"},{"key":"2019111906433378100_REF17","doi-asserted-by":"crossref","unstructured":"Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med. 1988;167: 219-224.","DOI":"10.1084\/jem.167.1.219"},{"key":"2019111906433378100_REF18","doi-asserted-by":"crossref","unstructured":"Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341: 1112-1120.","DOI":"10.1056\/NEJM199910073411503"},{"key":"2019111906433378100_REF19","doi-asserted-by":"crossref","unstructured":"Loughnan MS, Takatsu K, Harada N, Nossal GJ. T-cell-replacing factor (interleukin 5) induces expression of interleukin 2 receptors on murine splenic B cells. Proc Natl Acad Sci U S A. 1987; 84: 5399-5403.","DOI":"10.1073\/pnas.84.15.5399"},{"key":"2019111906433378100_REF20","doi-asserted-by":"crossref","unstructured":"Mishra A, Hogan SP, Brandt EB, Rothenberg ME. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol. 2002;168: 2464-2469.","DOI":"10.4049\/jimmunol.168.5.2464"},{"key":"2019111906433378100_REF21","doi-asserted-by":"crossref","unstructured":"Macias MP, Fitzpatrick LA, Brenneise I, McGarry MP, Lee JJ, Lee NA. Expression of IL-5 alters bone metabolism and induces ossification of the spleen in transgenic mice. J Clin Invest. 2001; 107: 949-959.","DOI":"10.1172\/JCI11232"},{"key":"2019111906433378100_REF22","doi-asserted-by":"crossref","unstructured":"Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990;172: 1425-1431.","DOI":"10.1084\/jem.172.5.1425"},{"key":"2019111906433378100_REF23","doi-asserted-by":"crossref","unstructured":"Hawley RG, Covarrubias L, Hawley T, Mintz B. Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells. Proc Natl Acad Sci U S A. 1987;84: 2406-2410.","DOI":"10.1073\/pnas.84.8.2406"},{"key":"2019111906433378100_REF24","doi-asserted-by":"crossref","unstructured":"Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR\/ABL. Blood. 2001;97: 1442-1450.","DOI":"10.1182\/blood.V97.5.1442"},{"key":"2019111906433378100_REF25","doi-asserted-by":"crossref","unstructured":"Yang S, Delgado R, King SR, et al. Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther. 1999;10: 123-132.","DOI":"10.1089\/10430349950019255"},{"key":"2019111906433378100_REF26","unstructured":"Williams DA, Tao W, Yang F, et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood. 2000;96: 1646-1654."},{"key":"2019111906433378100_REF27","doi-asserted-by":"crossref","unstructured":"Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1: 433-443.","DOI":"10.1016\/S1535-6108(02)00069-7"},{"key":"2019111906433378100_REF28","doi-asserted-by":"crossref","unstructured":"Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100: 238-245.","DOI":"10.1182\/blood.V100.1.238"},{"key":"2019111906433378100_REF29","doi-asserted-by":"crossref","unstructured":"le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91: 163-168.","DOI":"10.1093\/jnci\/91.2.163"},{"key":"2019111906433378100_REF30","doi-asserted-by":"crossref","unstructured":"Discombe G. Criteria of eosinophilia. Lancet. 1946;247: 195-196.","DOI":"10.1016\/S0140-6736(46)91306-2"},{"key":"2019111906433378100_REF31","doi-asserted-by":"crossref","unstructured":"Matthews AN, Friend DS, Zimmermann N, et al. Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci U S A. 1998;95: 6273-6278.","DOI":"10.1073\/pnas.95.11.6273"},{"key":"2019111906433378100_REF32","doi-asserted-by":"crossref","unstructured":"Brandt EB, Strait RT, Hershko D, et al. Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest. 2003;112: 1666-1677.","DOI":"10.1172\/JCI19785"},{"key":"2019111906433378100_REF33","doi-asserted-by":"crossref","unstructured":"Tateno H, Crocker PR, Paulson JC. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology. 2005;15: 1125-1135.","DOI":"10.1093\/glycob\/cwi097"},{"key":"2019111906433378100_","doi-asserted-by":"crossref","unstructured":"Zhang JQ, Biedermann B, Nitschke L, Crocker PR. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol. 2004;34: 1175-1184.","DOI":"10.1002\/eji.200324723"},{"key":"2019111906433378100_REF35","doi-asserted-by":"crossref","unstructured":"Angata T, Hingorani R, Varki NM, Varki A. Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters. J Biol Chem. 2001;276: 45128-45136.","DOI":"10.1074\/jbc.M108573200"},{"key":"2019111906433378100_REF36","doi-asserted-by":"crossref","unstructured":"Sriramarao P, von Andrian UH, Butcher EC, Bourdon MA, Broide DH. L-selectin and very late antigen-4 integrin promote eosinophil rolling at physiological shear rates in vivo. J Immunol. 1994;153: 4238-4246.","DOI":"10.4049\/jimmunol.153.9.4238"},{"key":"2019111906433378100_REF37","doi-asserted-by":"crossref","unstructured":"Jia GQ, Gonzalo JA, Hidalgo A, Wagner D, Cybulsky M, Gutierrez-Ramos JC. Selective eosinophil transendothelial migration triggered by eotaxin via modulation of Mac-1\/ICAM-1 and VLA-4\/VCAM-1 interactions. Int Immunol. 1999; 11: 1-10.","DOI":"10.1093\/intimm\/11.1.1"},{"key":"2019111906433378100_REF38","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994; 87: 746-754.","DOI":"10.1111\/j.1365-2141.1994.tb06734.x"},{"key":"2019111906433378100_REF39","doi-asserted-by":"crossref","unstructured":"Brito-Babapulle F. Clonal eosinophilic disorders and the hypereosinophilic syndrome. Blood Rev. 1997;11: 129-145.","DOI":"10.1016\/S0268-960X(97)90008-4"},{"key":"2019111906433378100_REF40","doi-asserted-by":"crossref","unstructured":"Gotlib V, Darji J, Bloomfield K, Chadburn A, Patel A, Braunschweig I. Eosinophilic variant of chronic myeloid leukemia with vascular complications. Leuk Lymphoma. 2003;44: 1609-1613.","DOI":"10.1080\/1042819031000156748"},{"key":"2019111906433378100_REF41","unstructured":"De Cock C, Lemaitre J, Deuvaert FE. Loeffler endomyocarditis: a clinical presentation as right ventricular tumor. J Heart Valve Dis. 1998;7: 668-671."},{"key":"2019111906433378100_REF42","unstructured":"Slungaard A, Vercellotti G, Zanjani E, Ascensao J, Jacob HS. Tumor-induced eosinophilia and endocardial fibrosis: evidence for ectopic eosinophilopoietin production and toxic O2 metabolite-mediated endothelial damage. Trans Assoc Am Physicians. 1982;95: 8-11."},{"key":"2019111906433378100_REF43","doi-asserted-by":"crossref","unstructured":"Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83: 2759-2779.","DOI":"10.1182\/blood.V83.10.2759.2759"},{"key":"2019111906433378100_REF44","doi-asserted-by":"crossref","unstructured":"Gotlib J, Cools J, Malone JM III, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103: 2879-2891.","DOI":"10.1182\/blood-2003-06-1824"},{"key":"2019111906433378100_REF45","doi-asserted-by":"crossref","unstructured":"Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy. 2004;59: 673-689.","DOI":"10.1111\/j.1398-9995.2004.00465.x"},{"key":"2019111906433378100_REF46","doi-asserted-by":"crossref","unstructured":"Sutton SA, Assa'ad AH, Rothenberg ME. Anti-IL-5 and hypereosinophilic syndromes. Clin Immunol. 2005;115: 51-60.","DOI":"10.1016\/j.clim.2005.02.006"},{"key":"2019111906433378100_REF47","doi-asserted-by":"crossref","unstructured":"Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103: 2939-2941.","DOI":"10.1182\/blood-2003-10-3620"},{"key":"2019111906433378100_REF48","doi-asserted-by":"crossref","unstructured":"Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113: 115-119.","DOI":"10.1016\/j.jaci.2003.10.049"},{"key":"2019111906433378100_REF49","doi-asserted-by":"crossref","unstructured":"Lamkhioued B, Gounni AS, Aldebert D, et al. Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Ann N Y Acad Sci. 1996;796: 203-208.","DOI":"10.1111\/j.1749-6632.1996.tb32582.x"},{"key":"2019111906433378100_REF50","doi-asserted-by":"crossref","unstructured":"Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101: 3391-3397.","DOI":"10.1182\/blood-2002-10-3103"},{"key":"2019111906433378100_REF51","doi-asserted-by":"crossref","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102: 3093-3096.","DOI":"10.1182\/blood-2003-05-1627"},{"key":"2019111906433378100_REF52","unstructured":"Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica. 2004;89: 871-873."},{"key":"2019111906433378100_REF53","doi-asserted-by":"crossref","unstructured":"Cools J, Quentmeier H, Huntly BJ, et al. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2004;103: 2802-2805.","DOI":"10.1182\/blood-2003-07-2479"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/10\/4071\/466221\/zh801006004071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/10\/4071\/466221\/zh801006004071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:19:11Z","timestamp":1683353951000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/10\/4071\/109797\/The-FIP1L1PDGFRA-fusion-gene-cooperates-with-IL5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,15]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,5,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-08-3153","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,15]]}}}